Hosted by the Pharmaceutical Safety Council, this conference keeps in‑line with prevailing regulatory trends and industrial pain‑points across the pharmaceutical sector. It centers on six key themes: implementation of updated regulations, revisions to Chinese Pharmacopoeia standards, end‑to‑end laboratory compliance, site‑wide pollution prevention and control, refined microbial management, and intelligent production control within workshops. It delivers in‑depth interpretations of revised contents in the newly‑updated Regulations for Implementation of the Drug Administration Law and the 2025 edition of the Chinese Pharmacopoeia. Meanwhile, participants discuss industry‑wide priorities such as pharmaceutical data integrity, compliance verification of pharmaceutical‑grade water, full‑scale GMP control, traceability of pharmaceutical contamination and microbial risk prevention. The exhibition draws practitioners engaged in quality control, laboratory operation, production technology, third‑party testing and R&D from pharmaceutical companies. It fosters robust interactions and productive exchanges among industry players, universities and research institutes.
Hippicrates’s booth attracted steady visitor traffic throughout the event. Drawing on its long‑standing expertise in pharmaceutical compliance and regulation‑aligned digital product portfolio, the company garnered widespread attention from industry peers. Its flagship offering unveiled at the show is the self‑developed OwlTrust® digital platform for quality and compliance. Built upon an integrated compliance‑management foundation, it encompasses seven core modules including document‑compliance administration, personnel qualification training, company‑wide quality management, closed‑loop electronic agreements, pharmacovigilance management, quality coordination for contract manufacturing, and dedicated controls for cell‑therapy projects. Its modular structure flexibly accommodates digital‑transformation requirements for pharmaceutical companies of varying sizes and diverse business segments.
Tailored to current operational layouts of drug manufacturers, Hippicrates showcased three full‑life‑cycle digital solutions: quality‑coordination systems for contract‑manufacturing projects, end‑to‑end cell‑quality management tools, and closed‑loop pharmacovigilance systems. These solutions serve in‑house production, outsourced manufacturing, cell‑based biomedicine and post‑marketing risk‑management scenarios, and comprehensively address demands for digital‑compliance development for pharmaceutical enterprises.
Most attending enterprises acknowledged tightening pharmaceutical oversight and frequent updates to regulatory and pharmacopoeia requirements. Conventional manual‑driven management can hardly satisfy standards for data integrity, full‑process traceability and compliant operations, making digital‑enabled efficiency‑improvement an urgent priority.
Hippicrates’s integrated digital solutions comply with full‑cycle pharmaceutical compliance requirements. They break down data silos spanning R&D, laboratory testing, manufacturing, quality assurance and pharmacovigilance. The platform helps organizations adhere to GMP requirements, adapt to digital‑oriented regulatory inspections and mitigate operational risks in line with industrial developments.
Hippicrates consistently focuses on the life‑health sector and specializes in digital‑compliance solutions for pharmaceutical businesses. It delivers cutting‑edge digital offerings to help drug manufacturers strengthen quality‑management frameworks, satisfy regulatory rules and advance digital‑transformation initiatives. Participation in the Hangzhou Pharmaceutical Quality and Safety Conference provided Hippicrates with a valuable chance to communicate deeply with market participants and identify real‑world client demands. Going forward, Hippicrates will keep pace with regulatory updates and industry developments, iteratively upgrade its products and solutions, refine application‑oriented technical services, empower pharmaceutical firms to safeguard drug quality and safety, and accelerate their digital‑upgrade journey.
